Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Salvage Therapy for Chronic Antibody-Mediated Rejection After Kidney Transplantation
ChiCTR2400080182Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in Chronic antibody-mediated rejection of kidney transplant (cABMR), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Change in urine protein from baseline at week 24 and Change in estimated glomerular filtration rate (eGFR) from baseline at week 24. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
Chronic antibody-mediated rejection of kidney transplant (cABMR)
Beyond the preview
Go deeper on ChiCTR2400080182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080182.